Table 3.
Univariate and multivariate analysis of factors according to OS in AGC patients treated with anti-PD-1 drugs in the first-line therapy.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (years) | ||||
| ≤65 | 1 (reference) | |||
| >65 | 1.883 (0.786-4.513) | 0.149 | – | – |
| Gender | ||||
| Male | 1 (reference) | |||
| Female | 0.985 (0.451-2.151) | 0.969 | – | – |
| Differentiation | ||||
| Poor | 1 (reference) | |||
| Moderate or well | 0.553 (0.207-1.477) | 0.231 | – | – |
| Location | 0.253 | |||
| Upper | 1 (reference) | |||
| Middle | 2.652 (0.912-7.707) | 0.073 | – | – |
| Low | 1.134 (0.410-3.134) | 0.808 | – | – |
| Others | 1.238 (0.318-4.820) | 0.758 | – | – |
| Metastatic site | ||||
| Peritoneal metastasis | ||||
| Negative | 1 (reference) | 1 (reference) | ||
| Positive | 3.244 (1.517-6.936) | 0.001 | 3.098 (1.446-6.634) | 0.004 |
| Liver metastasis | ||||
| Negative | 1 (reference) | |||
| Positive | 1.486 (0.685-3.221) | 0.313 | – | – |
| Lymph node metastasis | ||||
| Negative | 1 (reference) | |||
| Positive | 0.507 (0.220-1.171) | 0.105 | – | – |
| Lung metastasis | ||||
| Negative | 1 (reference) | |||
| Positive | 1.163 (0.401-3.369) | 0.781 | – | – |
| Number of metastatic sites | ||||
| ≤2 | 1 (reference) | 1 (reference) | ||
| ≥3 | 3.192 (1.482-6.874) | 0.002 | 1.296 (0.433-3.881) | 0.644 |
| ECOG PS | ||||
| 0-1 | 1 (reference) | 1 (reference) | ||
| ≥2 | 4.829 (1.092-21.350) | 0.022 | 3.200 (0.643-15.925) | 0.155 |
| First line chemotherapeutic regimen | 0.394 | |||
| Fluorouracil+Platinum | 1 (reference) | |||
| Fluorouracil+Taxanes | 0.974 (0.222-4.265) | 0.972 | – | – |
| Others | 1.775 (0.754-4.177) | 0.189 | – | – |
| Alcohol Consumption | ||||
| Abstinence or low risk | 1 (reference) | |||
| Hazardous or harmful | 0.629 (0.187-2.108) | 0.448 | – | – |
| NLR | ||||
| ≤3.11 | 1 (reference) | |||
| >3.11 | 1.679 (0.778-3.625) | 0.182 | – | – |
| PLR | ||||
| ≤243.33 | 1 (reference) | 1 (reference) | ||
| >243.33 | 2.959 (1.318-6.642) | 0.006 | 2.770 (1.234-6.219) | 0.014 |
| MLR | ||||
| ≤0.20 | 1 (reference) | 1 (reference) | ||
| >0.20 | 4.385 (1.036-18.569) | 0.028 | 2.777 (0.626-12.311) | 0.179 |
| dNLR | ||||
| ≤2.09 | 1 (reference) | |||
| >2.09 | 1.781 (0.825-3.842) | 0.136 | – | – |
| SII | ||||
| ≤1140.91 | 1 (reference) | |||
| >1140.91 | 1.947 (0.873-4.346) | 0.098 | – | – |
| LDH | ||||
| ≤250 | 1 (reference) | |||
| >250 | 1.191 (0.520-2.726) | 0.680 | – | – |
| CEA | ||||
| ≤5 | 1 (reference) | |||
| >5 | 0.591 (0.235-1.487) | 0.258 | – | – |
| CA199 | ||||
| ≤27 | 1 (reference) | |||
| >27 | 2.062 (0.836-5.083) | 0.108 | – | – |
| CA724 | ||||
| ≤8.2 | 1 (reference) | |||
| >8.2 | 1.239 (0.449-3.419) | 0.679 | – | – |
| Molecular classification | 0.813 | |||
| HER negative | 1 (reference) | |||
| HER positive | 0.674 (0.157-2.900) | 0.597 | – | – |
| Unknown | 1.173 (0.400-3.442) | 0.771 | – | – |